LMTK3, a key ERα regulator in breast cancer, stabilizes ERα via direct phosphorylation and promotes its transcription by inhibiting PKC, reducing AKT phosphorylation, and facilitating FOXO3 binding to the ESR1 promoter (157–159). This evidence concerns the gene AKT1 and breast carcinoma.